Présentation PowerPoint

[Virtual Presenter] Welcome to our presentation on Capixyl, a cutting-edge anti-aging hair care complex designed to promote healthy hair growth and prevent hair loss. Its unique blend of natural ingredients and scientifically-backed formula makes it poised to revolutionize the way we think about hair care. Let's dive into the world of Capixyl and explore its benefits and features..

[Audio] The hair treatment market has seen significant growth in recent years, driven by increasing awareness of the importance of hair health and the desire for effective solutions to address various hair concerns. Our understanding of hair biology has also advanced significantly, enabling the development of more targeted and effective treatments..

[Audio] Hair loss is a significant issue that affects millions of people worldwide. It's not just about physical appearance; it's also about self-esteem and confidence. Androgenetic alopecia, the most common type of hair loss, affects nearly half of men and possibly an equal number of women over 40 years old. In fact, two-thirds of American men will experience noticeable hair loss by the age of 35, and 25% of men start losing their hair even before reaching 21. These statistics highlight the widespread impact of hair loss, with estimates suggesting that 35 million men and 21 million women in the United States alone are affected. Similar trends are seen in other countries, including France, Japan, and China..

[Audio] Although the causes of hair loss are not yet fully understood, it can result from several factors. These include genetic predisposition, hormonal changes or imbalances, such as those experienced during childbirth or menopause, improper nutrition, stress, diseases like diabetes or lupus, medications, seasonal changes, and aging and photo-aging. Hair loss can be either permanent or temporary, and it affects both men and women. While men tend to experience a greater degree of loss, particularly around the temples and vertex, women may also be affected, especially after menopause, when up to 75% of women over the age of 65 may experience hair loss..

[Audio] The market opportunity for hair loss treatment is significant, with American hair loss sufferers spending over $3.5 billion annually. Various products address this condition through different mechanisms of action, including vasodilation, hormonal modification, and collagen rigidification. These products have varying degrees of effectiveness and side effects, such as burning, irritation, and chest pain..

[Audio] Thinning hair and hair loss products account for 28% of all hair care treatments in the market. Prestige over-the-counter anti-hair loss treatments have modernized and brought credibility to this category. Brands introduce innovative natural and high-tech active ingredients, targeting both men and women. Examples include DHC's Medicated Hair Tonic, Biotherm's Regenetic Anti-Hair Loss Serum, and Schwarzkopf & Henkel's Hair Tonic for Women. These products extend the "anagen" stage, strengthen and revitalize hair, and maintain the condition of the hair follicle. They address premature aging and collagen rigidification around the root. With the demand for affordable, effective, and image-enhancing solutions, there is an opportunity for high-performance, clinically-proven anti-hair loss treatments..

[Audio] Hair appears more complex than it initially seems because it is composed of two main structures: the hair shaft above the skin and the hair follicle beneath the skin. At the base of the follicle lies the dermal papilla and extracellular matrix. As new cells grow within these areas, they push the previous cells upwards, forming the hair. The dermal papilla plays a vital role in dermal-epidermal interactions, making it essential for both hair formation and growth cycles..

[Audio] Each hair follicle has the potential to produce multiple hairs throughout its lifetime. On average, we carry around 100000 hair follicles, each capable of producing numerous hairs. The hair follicle growth cycle consists of three distinct phases. During the anagen phase, hair grows rapidly for two to six years, making up approximately 70 to 85 percent of our total hair mass. Following this growth period, the catagen phase occurs, where the hair bulb separates from the dermal papilla, and the follicle migrates towards the scalp, lasting about two to three weeks. Finally, the telogen phase takes place, where hair remains attached to the follicle for about 100 days before falling out and being replaced by a new hair in the anagen phase..

[Audio] The process of hair loss starts with the shortening of the anagen phase due to dihydrotestosterone, or DHT, which leads to miniaturization of the follicles. Since there is no hormonal dysfunction, the body's hormone levels remain balanced. The integrity of extracellular matrix proteins is essential for maintaining healthy hair follicles, but when these proteins cease to be renewed, the follicles shrink and lose their ability to anchor hair. Moreover, the absence of inflammation indicates that there is no immune response involved in the hair loss process. Conversely, if inflammation occurs, it disrupts the normal hair growth cycle..

[Audio] Our anti-aging hair care complex works through three main mechanisms. Modulation of DHT slows down the progression of hair loss by preventing miniaturization of hair follicles. Ensuring the integrity of extracellular matrix proteins maintains healthy hair follicles. Addressing inflammation reduces its impact on the hair growth cycle. By addressing these factors, our complex promotes healthy hair growth and prevents further hair loss..

[Audio] DHT is formed through the conversion of testosterone by the enzyme 5-alpha-reductase. This process causes hair loss by reducing the length of time the hair grows, leading to smaller and thinner hair follicles. The enzyme also plays a role in other bodily functions such as bile acid production and hormone regulation. As a result, DHT contributes to the development of conditions like acne, prostate cancer, and male pattern baldness..

[Audio] When the extracellular matrix, or ECM, loses its integrity, it can have a significant impact on the health of our hair. This is because the size of our hair follicles is determined by two main factors: the volume of their dermal papillas and the volume of the extracellular matrix itself. A healthy dermal papilla produces good ECM proteins like collagen type III and anchoring fibers like laminin and collagen VII, which help to anchor our hair securely in the surrounding tissue. However, if the ECM is not properly renewed, our hair follicles may begin to shrink over time, leading to a gradual loss of vigor and thinning. As this process continues, our hair follicles become smaller and smaller, until they eventually miniaturize and fall out..

[Audio] The inflammatory response plays a crucial role in the development of androgenetic alopecia. The production of pro-inflammatory cytokines leads to alterations in the extracellular matrix, ultimately resulting in hair follicle degradation and hair loss. This process is triggered by various factors such as internal stresses, chemical exposure, aging, climatic variations, and hormonal imbalances, particularly the presence of dihydrotestosterone (DHT). As a result, the hair follicles undergo miniaturization, leading to thinning and eventually, hair loss..

Focus on Capixyl™.

[Audio] Capixyl™ combines two key ingredients, Biochanin A extracted from Red clover and Acetyl tetrapeptide-3, a biomimetic peptide derived from a signal peptide. Biochanin A acts as an effective inhibitor of 5-alpha reductase, thereby regulating the conversion of testosterone to DHT, a hormone linked to androgenic alopecia. On the other hand, Acetyl tetrapeptide-3 directly affects the hair follicle, stimulating tissue remodeling and increasing its size for better hair anchoring and vitality. With this unique combination, Capixyl™ offers a clinically proven solution for addressing hair loss issues..

Clinical study on hair loss.

[Audio] Thirty volunteers with androgenetic alopecia, averaging 46 years old, were selected for this clinical trial. They did not have any underlying health issues, such as iron deficiency anemia or thyroid-related conditions. The participants had to meet specific criteria, including having fewer than 200 hairs on the treated area and being in a state of low hair growth activity, with less than 70% of their hairs in the anagen phase. Fifteen participants received our Capixyl™ lotion, containing 5% of the active ingredient, while another fifteen received a placebo. Both formulations consisted of 75% water and 20% alcohol. Participants applied twenty drops of either the Capixyl™ lotion or placebo once daily at night for a period of four months. Digital trichograms were taken using the TrichoScan professional device at the beginning and end of the study to assess the effectiveness of our treatment..

[Audio] To analyze the hair growth cycle, we use a technique called TrichoScan. This involves shaving a small area of the scalp, approximately 1.8 square centimeters, and then taking a picture of the same area three days later to evaluate the anagen and telogen phases. The anagen phase is defined as a growth rate of 0.3 millimeters per day. We then analyze the results using microscopy and automatic digital image analysis, identifying the original hair, detected hair, marked hair, and separating the anagen and telogen hair. The green color represents the anagen phase, while red indicates the telogen phase..

[Audio] The results show that more than 70 percent of the volunteers experienced an improvement in their condition. This indicates that Capixyl has been effective in promoting hair growth by increasing the anagen hair density. At the same time, it has also been successful in stopping hair loss by reducing the telogen hair density..

[Audio] The results reveal that Capixyl™ boosts the anagen-to-telogen hair ratio by 46%, signifying an activation of hair growth. Consequently, treatment proves effective in halting hair loss and fostering new hair growth. On the contrary, the placebo group exhibits a decline in this ratio of 33%, implying a deterioration of alopecia. These findings substantiate the potency of Capixyl™ in stimulating hair growth and diminishing hair loss..

[Audio] The results clearly demonstrate a significant increase in the number of hairs. Before-and-after images show a clear decrease in alopecia, indicating the effectiveness of Capixyl. We can confidently state that this complex offers a reliable solution for individuals experiencing hair loss. The visual evidence powerfully illustrates its capacity to promote healthy hair growth..

[Audio] Capixyl has been demonstrated to diminish inflammation by lowering the production of IL-8, a crucial inflammatory mediator. This diminution in inflammation can facilitate a healthy setting for hair growth..

[Audio] The aim of this experiment was to measure the decrease in IL-8 production, a pro-inflammatory cytokine triggered by a natural mediator. Inflammation is known to contribute to alopecia, a common condition characterized by hair loss. To achieve this goal, we employed a protocol where inflammation was induced in human fibroblasts using IL-1a, a natural mediator. The fibroblasts were then incubated with or without Capixyl™, a potential therapeutic agent, at concentrations ranging from 0.5% to 1%, along with a positive control, dexamethasone. Following 24 hours, we utilized an enzyme immunoassay kit to quantify the levels of IL-8 produced. This study sought to examine the impact of Capixyl™ on IL-8 production, offering valuable insights into its potential role in regulating inflammation and promoting healthy hair growth..

[Audio] The study investigated the impact of Capixyl™ on interleukin-8 production in human fibroblasts. Inflammation was induced in the cells using IL-1 alpha, a natural trigger. Next, the fibroblasts were treated with or without Capixyl™, spanning concentrations from 0.5% to 1%, or dexamethasone, a benchmark substance, for 24 hours. The findings revealed that Capixyl™ reduced the release of pro-inflammatory cytokines, demonstrating a synergistic effect when compared to red clover extract alone. This discovery implies that Capixyl™ might significantly contribute to decreasing inflammation, a primary cause of alopecia..

[Audio] Biochanin A, which is present in the red clover extract, has modulated dihydrotestosterone, or DHT, by inhibiting 5-alpha reductase. This enzyme plays a crucial role in the conversion of testosterone to DHT, a hormone linked to hair loss. By inhibiting this enzyme, Biochanin A may have helped regulate the balance of hormones involved in hair growth and maintenance..

[Audio] The inhibition of 5-alpha reductase activity by Biochanin A has been shown to occur through this study, which compared it to the well-known inhibitor EGCG. The protocol involved measuring DHT production from testosterone in the presence of either type 1 or 2 human 5-alpha reductase enzymes. Radio-labelled testosterone was used, and its amount was determined using thin-layer chromatography and scanning. This discovery confirms the potential of Biochanin A in reducing androgenic alopecia by decreasing DHT production..

[Audio] Biochanin A has been found to inhibit 5-alpha reductase activity, thereby confirming its impact on reducing dihydrotestosterone, or DHT, production, ultimately leading to a decrease in androgenic alopecia..

[Audio] The peptide Acetyl tetrapeptide-3 stimulates the production of anchoring proteins leading to the renewal of the follicular extracellular matrix. This process involves the stimulation of various proteins including collagen types III and VII as well as laminin. By promoting the synthesis of these proteins Acetyl tetrapeptide-3 plays a crucial role in maintaining the integrity of the hair follicle's anchorage site..

[Audio] The objective of this study was to quantify the total collagen synthesis induced by Acetyl tetrapeptide-3 on fibroblasts. To achieve this goal, we employed the hydroxy proline dosage method, which assesses the stimulating capacity of a product on fibroblast collagen production. Our protocol involved treating human fibroblasts with Acetyl tetrapeptide-3 at a concentration of 10-7M, equivalent to approximately 0.016% Capixyl™ solution, for a period of seven days. The hydroxyproline dosage was then evaluated using the Chloramine T reaction and measured by optical density at 540 nanometers, compared to a range standard..

[Audio] Acetyl tetrapeptide-3 plays a crucial role in promoting collagen synthesis by inducing the synthesis of hydroxyproline, ultimately leading to increased collagen production. This process enhances the integrity of the extracellular matrix, allowing for optimal hair follicle anchoring. By stimulating collagen production, acetyl tetrapeptide-3 helps maintain healthy hair growth and structure..

[Audio] In this study, we aimed to quantify the synthesis of laminin and type III collagen induced by acetyl tetrapeptide-3 on human fibroblasts. Our results demonstrate that this molecule stimulates the production of these essential proteins, which play a crucial role in maintaining the integrity of the extracellular matrix and promoting hair follicle growth. To achieve this goal, we treated human fibroblasts with acetyl tetrapeptide-3 at a concentration equivalent to 0.016% of the Capixyl™ solution for three days. We then used specific antibodies linked to a fluorochrome to detect and quantify the proteins produced. The images obtained through confocal microscopy allowed us to compare and analyze the fluorescence intensity, providing valuable insights into the effects of acetyl tetrapeptide-3 on protein synthesis. This research underscores the potential benefits of stimulating ECM protein production for improving hair health and promoting healthy hair growth..

[Audio] Acetyl tetrapeptide-3 plays a crucial role in protein synthesis by inducing the synthesis of laminin and type III collagen in fibroblasts. This stimulation also affects the dermal papilla's extracellular matrix proteins, leading to improved hair follicle size and anchoring..

[Audio] The objective of this study is to quantify the type VII collagen synthesis induced by Acetyl tetrapeptide-3 on human skin explants. This protein is a major constituent of the anchoring fibrils and is located in the basement membrane around the papilla. Human skin explants were pre-treated with dermocorticoïds to reproduce a natural aging pattern. These dermocorticoids are known to decrease the growth of hair papilla cells. The skin explants were then treated with Acetyl tetrapeptide-3 for two days. Type VII collagen was detected using specific antibodies and quantified through microscopy. The results were obtained by comparing images and labeling quantification..

[Audio] Acetyl tetrapeptide-3 is the key component in this formula, playing a crucial role in promoting hair health. It provides a repairing effect at the dermal-epidermal junction level, improving hair anchoring, allowing hair to grow stronger and more resilient. This is achieved through its ability to stimulate collagen VII synthesis, which helps to fortify the hair follicle and promote healthy hair growth..

[Audio] In this study, we measured the growth of human hair after eight days in culture with or without Acetyl tetrapeptide-3. We followed a specific protocol to achieve this objective. Firstly, we recovered human hair follicles from human scalps during their active growth phase, known as anagen. Then, we cultured these follicles with or without Acetyl tetrapeptide-3 at a concentration equivalent to 0.0006 percent of the Capixyl solution, following the Philpot method. Finally, we evaluated the growth of the follicles using a micrometer under an optical microscope..

[Audio] Acetyl tetrapeptide-3 has improved hair growth by 35%. In ex vivo studies, it stimulated hair growth compared to untreated hair. This peptide promotes healthy hair development..

[Audio] In this comparative study, we measured the growth speed of hair shafts on isolated human hair follicles cultured with Acetyl tetrapeptide-3, comparing it to Minoxidil. We recovered human hair follicles from anagen phase scalp tissue and cultured them with either Acetyl tetrapeptide-3 at 10-7M or Minoxidil at 120 times 10-7M for seven days using the Philpot method. After treatment, we evaluated hair growth using a micrometer under an optical microscope and measured the normalized activity, representing the hair growth induced by the treatment..

[Audio] The results of our comparative study reveal that the hair growth activity of our treatment, which contains Acetyl tetrapeptide-3, outperforms that of Minoxidil, a renowned reference hair growth product. Specifically, our treatment displays a notable 156% surge in hair growth activity relative to untreated hair, whereas Minoxidil exhibits merely a 52% increase. This underscores the superior efficacy of our treatment in stimulating hair growth..

New Clinical Results.

[Audio] Eyelashes share similarities with scalp hair in terms of their structure and development. Approximately 100 to 200 eyelashes are found on the upper lid, ranging in length from 8 to 12 millimeters. In contrast, the lower lid has around 75 to 100 eyelashes, measuring between 6 and 8 millimeters. Unlike the scalp, the eyelid exhibits a thinner epidermis and lacks a hypodermis. Eyelash follicles display the same overall structure as scalp hair follicles, although they are significantly shorter due to a shorter hair cycle. This similarity in morphology is confirmed through specific labeling with ECM proteins and antibodies. Moreover, after the age of 40, the number of eyelashes tends to decline, becoming thinner in the process..

[Audio] To evaluate the lash density, photographs of the upper lashes are taken at D0, 4 weeks, and 8 weeks using a camera fixed on a biomicroscope. The number of lashes in the specific area to be analyzed is then counted. The surface where the lashes grow is measured next. Finally, the lash density is determined by combining these measurements. This process enables assessment of the changes in lash density over time..

[Audio] In this evaluation, we observed a significant increase in lash density, with a notable improvement of plus nine percent. This increase can reach up to twenty-seven percent, demonstrating the effectiveness of Capixyl in promoting healthy lash growth. Furthermore, our results show that after eight weeks of application, ninety-three percent of subjects experienced an impact on their lash density, with seventy-three percent showing a noticeable improvement after four weeks. These findings confirm that Capixyl induces a clear and significant increase in lash density, resulting from both increased new lash growth and decreased falling lashes..

[Audio] In this evaluation, we assess the number of new lashes formed during the treatment period. The characteristics of these young lashes are compared with those of adult lashes, revealing distinct features such as less coloring, thinner diameter, and shorter length. Photographs of the upper lashes are taken at three time points: Day 0, four weeks, and eight weeks, using a camera attached to a biomicroscope. The images are then used to accurately count the number of new lashes based on their morphology and characteristics, enabling us to track the growth and development of new lashes over time..

[Audio] The evaluation reveals that the number of new lashes has increased by 45.5% after eight weeks of using Capixyl. This significant improvement was not observed in the placebo group, where no noticeable effect was detected. Instead, Capixyl showed a remarkable impact, leading to a considerable enhancement in the number of new lashes..

[Audio] The results show that the evolution of lash length is three and five times better after applying Capixyl compared to the placebo group. This significant improvement was observed after four and eight weeks of treatment. In fact, 73% of participants experienced an increase in lash length after eight weeks, with some individuals showing up to 0.70 millimeter growth after just four weeks. These findings demonstrate that Capixyl effectively promotes lash growth, even after a short period of use..

[Audio] The evaluation of the lash length reveals that there was no significant change from time zero to four weeks in Volume Three. Nevertheless, by eight weeks, a noticeable increase in lash length becomes apparent. Similarly, in Volume Two, there was no significant change from time zero to four weeks, but by eight weeks, a notable growth in lash length is observed. These findings imply that our anti-aging hair care complex may have a positive influence on the health and appearance of eyelashes over time..

[Audio] The results from Volume #16 demonstrate that after four weeks, there was up to 0.7 millimeter growth in lash length. This growth continued up to eight weeks, showing the effectiveness of our anti-aging hair care complex in promoting healthy lash development..

[Audio] Seventy percent of consumers reported that their eyelids seemed denser, with thicker lashes. Furthermore, seventy-three percent of participants noted that their lashes appeared longer, while seventy-six percent experienced a fuller lash fringe. Additionally, ninety-one percent of consumers reported that their lashes fell out less frequently. Overall, our results demonstrate that Capixyl™ effectively enhances the appearance of eyelashes, leading to a positive opinion among users..

[Audio] Capixyl™ has been demonstrated to halt hair loss while concurrently inducing hair growth. This outcome is accomplished through its capacity to diminish inflammation, both clinically and in vitro. The comparative study underscores the superiority of Capixyl™ over Minoxidil in decreasing IL-8 levels. Moreover, Capixyl™ regulates DHT, inhibiting 5-alpha reductase via Biochanin A. This results in the renewal of follicular ECM and the stimulation of anchoring proteins. Furthermore, Acetyl tetrapeptide-3 stimulates the production of collagen types III, VII, and laminin. These mechanisms collectively contribute to the efficacy of Capixyl™ in fostering healthy hair growth and preventing hair loss..

[Audio] The key benefits of Capixyl™ lie in its ability to inhibit the conversion of testosterone to DHT, thereby preventing the miniaturization of follicles. Additionally, it promotes the renewal of ECM proteins, leading to better hair anchoring. Furthermore, Capixyl™ reduces inflammation, allowing for a normal hair cycle..